Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management

Cash position of EUR 44.8m provides funding visibility only through Q3 2026. FY2025 results show revenue and other income of EUR 9m, operating expenses of EUR 63m, and R&D expenses down 16% YoY to EUR 43.6m; stock ticked up 1.56% to EUR 1.30 in premarket trading. Management is prioritizing three core assets (lacunamab, IPH4502, monalizumab), pursuing non-dilutive financing and partnerships, and executing a workforce restructuring to extend runway, but limited cash and high opex remain execution risks.

Analysis

Innate’s portfolio construction (one late confirmatory oncology program, one early-stage ADC built on a differentiated payload/linker, and partnered immuno-oncology assets) creates multiple, non‑correlated binary outcomes that a single financing decision will aggregate into a single equity price path. A non-dilutive royalty or milestone deal shifts future economics toward lower near-term cash but preserves upside optionality for equity holders; an equity raise compresses per-share optionality and materially increases the probability that the market will revalue the company on a multiples basis rather than on program-level option value.

IPH4502’s mechanistic differentiation (exatecan payload, hydrophilic linker and non-overlapping epitope) is the kind of profile that could re-price the small cohort ADC peer set if topline signals hold — not just direct competitors but also suppliers of payloads/linkers and CRO capacity may face capacity re‑allocation and pricing power. Conversely, manufacturing/CMC scale-up for TOP1-ADCs and payload sourcing are underappreciated execution risks that can add 6–12 month delays and non-trivial cash outlays, making partnership terms (co-fund vs. royalty) the key determinant of dilution vs. timeline.

The largest external lever is the large-partner readout and ensuing commercial choices: a favorable readout operated by a big pharma partner will flow value via milestones/royalties with low cash-in-the-door near term but high optionality; a neutral/failure outcome forces either accelerated partnering on worse economics or deeper dilution. For investors, the right play is asymmetric exposure that caps downside from financing/dilution while keeping meaningful upside to program derisking or an M&A takeout.

Key Decisions for Investors

• Long IPHA via limited‑cost upside: buy IPHA Jan 2027 2.50 EUR calls (or nearest liquid long‑dated calls) sized 2–3% NAV. Rationale: asymmetric payoff to clinical/partnering catalysts with capped premium loss; catalyst window 6–12 months. Risk: total premium loss if programs disappoint or a dilutive raise collapses implied move.
• Equity + hedge: establish a small long equity position in IPHA (1–2% NAV) and buy Sep 2026 1.00 EUR puts to cap downside through the likely financing window. Rationale: protects versus dilution/near‑term binary while leaving upside to late‑stage readouts or partnership announcements. Cost: put premium reduces net exposure but materially lowers ruin risk.
• Event bet on partner de‑risking: buy AZN 6–12 month call spread sized 0.5–1% NAV (buy near‑the‑money calls, sell higher strike) to play upside from a positive partner‑led readout. Rationale: limited-cost asymmetric gain if the partner's trial readout materially de-risks the partnered IO asset and lifts royalty/profit-share expectations; downside limited to spread cost.
• Risk control note: avoid naked long IPHA equity >5% NAV into the financing window; prefer option-based or hedged structures given high execution and dilution tail risk — treat positions as binary event trades and size accordingly.